Corcept Therapeutics Inc
Research Corcept Therapeutics Inc (CORT) on Bullrun: market cap USD 13.08B, P/E 289.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCORT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 13.08B
- P/E289.4
- Financial periodQ2 2026
- RevenueUSD 256.15M
- Net incomeUSD 42.99M
- Free cash flowUSD 31.02M
- Gross margin98.4%
Valuation Snapshot
latest market cap is USD 13.08B; P/E is 289.4.
Peer valuation comparison
Latest P/E is 289.44x versus a Healthcare sector median of 24.61x (1076.2% above).
Latest P/E is 289.44x versus a United States median of 23.85x (1113.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 761.41M | USD 99.65M | USD 141.79M | 98.3% | 0.82 | USD 120.50M | USD 6.11M | USD 647.81M |
| FY2024 | USD 675.04M | USD 141.21M | USD 196.12M | 98.4% | 1.23 | USD 127.67M | USD 6.94M | USD 679.59M |
| FY2023 | USD 482.38M | USD 106.14M | USD 126.54M | 98.7% | 0.94 | USD 135.55M | USD 151.00K | USD 506.71M |
| FY2022 | USD 401.86M | USD 101.42M | USD 119.91M | 98.7% | 0.87 | USD 66.33M | USD 1.14M | USD 501.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 13.08B | 289.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.69B | 42.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.30B | 41.0 | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.35B | 40.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.19B | 20.5 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.10B | 22.0 | n/a | n/a |
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
ETFs that hold Corcept Therapeutics Inc
Corcept Therapeutics Inc is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation | 4.22% | 0.60% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Corcept Therapeutics Inc's market cap?
Corcept Therapeutics Inc's market capitalization is USD 13.08B.
What is Corcept Therapeutics Inc's P/E ratio?
Corcept Therapeutics Inc's price-to-earnings (P/E) ratio is 289.4.
What does Corcept Therapeutics Inc do?
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.